급성 뇌졸중의 증상을 보인 Cefepime뇌병증 = Cefepime Induced Encephalopathy Mimicking Acute Stroke

다국어 초록 (Multilingual Abstract)

Cefepime is a fourth-generation cephalosporin, developed in 1994, and is well known for its adverse effects. In 2002, the Food and Drug Administration adjusted the labeling to account for increased risk of seizures, encephalopathy and myoclonus, especially in the setting of renal impairment. Here we present a case of an 86-year-old female, undergoing Cefepime treatment, with encephalopathy mimicking acute stroke.

참고문헌 (Reference)

1 Jallon P, "Severe but reversible encephalopathy associated with cefepime" 30 : 383-386, 2000

2 Maganti R, "Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function" 8 : 312-314, 2006

3 Bazan JA, "Newer beta-lactam antibiotics : doripenem, ceftobiprole, ceftaroline, and cefepime" 95 : 743-760, 2011

4 Chow KM, "Neurotoxicity induced by beta-lactam antibiotics : from bench to bedside" 24 : 649-653, 2005

5 U.S. Food & Drug Administration, "FDA drug safety communication:Cefepime and risk of seizurein patients not receiving dosage adjustmnets for kidney impairment"

6 Burgess SV, "Evaluating outcomes of alternative dosing strategies for cefepime : a qualitative systematic review" 49 : 311-322, 2015

7 Yahav D, "Efficacy and safety of cefepime : a systematic review and meta-analysis" 7 : 338-348, 2007

8 Kwon J, "Cefepime-induced aphasic status epilepticus mimicking acute stroke" 4 : 85-87, 2014

9 Isitan C, "Cefepime induced neurotoxicity : a case series and review of the literature" 8 : 40-43, 2017

10 Martin SI, "Beta-lactam antibiotics : newer formulations and newer agents" 18 : 603-619, 2004